Chats with Chaudhrey

17 September 2024

Angiex and Abzena CEOs Discuss Collaboration on AGX101 in Chats with Chaudhrey Podcast

In the latest episode of Chats with Chaudhrey, Paul Jaminet, CEO of Angiex, and Matthew Stober, CEO of Abzena, sat down to discuss their successful collaboration on AGX101, a first-in-class TM4SF1-directed antibody-drug conjugate (ADC). AGX101, which recently entered Phase I clinical trials, represents a novel approach to cancer therapy by targeting blood vessels in tumors. The discussion focused on how the partnership between Angiex and Abzena came to be, with Abzena providing crucial development and cGMP manufacturing support for the trial.

During the conversation, Jaminet and Stober outlined the reasons Angiex selected Abzena as their CDMO partner, citing Abzena’s expertise in biologics and their alignment with Angiex’s mission. They also shared insights on the working relationship, how it has evolved, and what the future holds for AGX101 and their ongoing partnership. Both executives weighed in on the future of ADCs, with Jaminet noting the growing interest and investment in the field over the past 18 months.

Hosted by Rizwan Chaudhrey, Chats with Chaudhrey offers viewers a platform to hear directly from industry leaders. Chaudhrey asked a series of engaging questions that provided in-depth perspectives on both companies’ missions and strategies, as well as their views on the future of ADC therapies. The episode highlights the importance of strategic collaborations in advancing cutting-edge cancer treatments and how Angiex and Abzena are working together to drive progress in oncology.


About Angiex

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. The lead product, AGX101, has advanced through pre-clinical development and is about to begin Phase 1 clinical trials. To learn more about Angiex...